BioCryst Pharmaceuticals | BCRX - Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
Alnylam Pharmaceuticals USD 282.51M 2.55M 2026-03
BioCryst Pharmaceuticals USD 95.78M 12.77M 2025-12
Chugai Pharma JPY 28.9B 8.02B 2026-03
Daiichi Sankyo JPY 228.23B 39.15B 2025-12
DBV Technologies USD 13.4M 8.14M 2026-03
Enanta Pharmaceuticals USD -1.05 0.31 2024-12
Gilead Sciences USD 1.45B 326M 2026-03
GlaxoSmithKline GBP 2.12B 558M 2026-03
Glaxosmithkline GBP 2.12B 1.44B 2026-03
Incyte USD 328.1M 62.31M 2026-03
Ionis Pharmaceuticals USD 151M 21M 2026-03
Karyopharm Therapeutics USD 9.56M 17.63M 2025-12
Neurocrine Biosciences USD 318.5M 16.7M 2026-03
Novavax USD 25.53M 1.34M 2025-12
PTC Therapeutics USD 73.89M 13.31M 2026-03
Regeneron Pharmaceuticals USD 647.7M 127.3M 2026-03
Roche Holding CHF 7.28B 3.99B 2025-12
Sarepta Therapeutics USD 54.03M 51.35M 2026-03
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
Vertex Pharmaceuticals USD 493.7M 6.7M 2026-03